日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

HDAC inhibitor tucidinostat and metronomic capecitabine plus endocrine therapy for patients with HR-positive HER2-negative advanced breast cancer after CDK4/6 inhibitors treatment: clinical findings and exploratory circulating tumor cell and ctDNA biomarker analyses of a multicenter, phase 2 study (SYSUCC-020 trial)

HDAC抑制剂tucidinostat和节拍式卡培他滨联合内分泌治疗用于CDK4/6抑制剂治疗后HR阳性HER2阴性晚期乳腺癌患者：一项多中心2期研究的临床结果和探索性循环肿瘤细胞和ctDNA生物标志物分析（SYSUCC-020试验）

期刊:Signal Transduction and Targeted Therapy
影响因子:52.7
doi:10.1038/s41392-026-02632-5
Wu, Huai-Liang; Xia, Wen; Xu, Zhengyang; Zhou, Hanxing; Chen, Limin; Lu, Yongkui; Liu, Xinlan; Pang, Danmei; Liu, Yan; Lu, Qianyi; Xu, Fei; An, Xin; Huang, Jiajia; Jiang, Kuikui; Zhang, Jingmin; Cai, Yili; Hong, Ruoxi; Zheng, Qiufan; Wang, Shusen
CDK4
肿瘤
HER2
肿瘤免疫
乳腺癌
细胞生物学
肿瘤细胞
发表日期：2026
文献求助 收藏

Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2 positive metastatic breast cancer: long term survival results from randomised phase 3 PHILA trial

吡咯替尼或安慰剂联合曲妥珠单抗和多西他赛治疗HER2阳性转移性乳腺癌：随机3期PHILA试验的长期生存结果

期刊:Bmj-British Medical Journal
影响因子:42.7
doi:10.1136/bmj-2025-087259
Ma, Fei; Yan, Min; Li, Wei; Ouyang, Quchang; Tong, Zhongsheng; Teng, Yuee; Wang, Yongsheng; Wang, Shusen; Geng, Cuizhi; Luo, Ting; Zhong, Jincai; Zhang, Qingyuan; Liu, Qiang; Zeng, Xiaohua; Sun, Tao; Mo, Qinguo; Zhou, Shoubing; Li, Peidong; Cheng, Jing; Wang, Xiaojia; Nie, Jianyun; Yang, Jin; Wu, Xinhong; Wang, Xinshuai; Li, Huiping; Yao, Guangyu; Fan, Yang; Lin, Jiaman; Zhu, Xiaoyu; Xu, Binghe
HER2
肿瘤
肿瘤免疫
乳腺癌
发表日期：2026
文献求助 收藏

Corrigendum to "Cu(II)-baicalein enhance paracrine effect and regenerative function of stem cells in patients with diabetes"

关于“Cu(II)-黄芩苷增强糖尿病患者干细胞的旁分泌效应和再生功能”的更正

期刊:Bioactive Materials
影响因子:20.3
doi:10.1016/j.bioactmat.2025.08.006
Liu, Kaijing; Li, Ruihao; Wang, Shusen; Fu, Xue; Zhu, Ni; Liang, Xiaoyu; Li, Huiyang; Wang, Xiaoli; Wang, Le; Li, Yongjun; Dai, Jianwu; Yang, Jing
干细胞
糖尿病
发育与干细胞
代谢
细胞生物学
发表日期：2026
文献求助 收藏

Extracellular matrix-derived mechanical force induces CDK4/6 inhibitor resistance by inhibiting NEK10 dependent cell cycle regulation in breast cancer

细胞外基质衍生的机械力通过抑制NEK10依赖的细胞周期调控，诱导乳腺癌细胞产生CDK4/6抑制剂耐药性。

期刊:International Journal of Surgery
影响因子:10.1
doi:10.1097/JS9.0000000000004527
Li, Cong; Wang, Jian; Jin, Yuming; Huang, Yumeng; Hong, Ruoxi; Chen, Dongshao; Lin, Shaoyan; Chen, Limin; Wu, Huailiang; Du, Ting; Xu, Binghe; Wang, Wan; Wang, Shusen
CDK4
肿瘤
肿瘤免疫
信号转导
乳腺癌
NEK1
细胞生物学
发表日期：2026
文献求助 收藏

Advances in TROP2-targeted antibody-drug conjugates for breast cancer therapy: into the new era

TROP2靶向抗体药物偶联物在乳腺癌治疗中的进展：迈入新时代

期刊:Cancer Biology & Medicine
影响因子:8.4
doi:10.20892/j.issn.2095-3941.2025.0504
Jiang, Kuikui; Wang, Shusen
肿瘤
肿瘤免疫
乳腺癌
发表日期：2026
文献求助 收藏

Hydrodynamics and Film Formation Mechanism Studies on Aqueous Polyurethane Coatings in Printing

印刷用水性聚氨酯涂料的流体动力学和成膜机理研究

期刊:ACS Omega
影响因子:4.3
doi:10.1021/acsomega.5c11349
Liu, Yuegang; Zhao, Xiuhua; Jiang, Guoxian; Ma, Jiaxing; Xie, Kaifang; Feng, Junying; Zheng, Changsheng; Wang, Shusen
发表日期：2026
文献求助 收藏

Chinese expert consensus on endocrine therapy for breast cancer (2026 edition)

中国乳腺癌内分泌治疗专家共识（2026版）

期刊:Translational Breast Cancer Research
影响因子:1.4
doi:10.21037/tbcr-2025-1-71
Yuan, Yang; Yin, Yongmei; Wang, Shu; Liu, Yueping; Yang, Jin; Yan, Min; Mo, Xueli; Pan, Yueyin; Wang, Xiaojia; Wang, Haibo; Li, Jianbin; Wang, Shusen; Wu, Jiong; Song, Erwei; Jiang, Zefei
肿瘤
肿瘤免疫
乳腺癌
发表日期：2026
文献求助 收藏

ACE-Breast-02: a randomized phase III trial of ARX788 versus lapatinib plus capecitabine for HER2-positive advanced breast cancer

ACE-Breast-02：一项比较 ARX788 与拉帕替尼联合卡培他滨治疗 HER2 阳性晚期乳腺癌的随机 III 期试验

期刊:Signal Transduction and Targeted Therapy
影响因子:52.7
doi:10.1038/s41392-025-02149-3
Hu, Xichun; Zhang, Qingyuan; Wang, Leiping; Zhang, Jian; Ouyang, Quchang; Wang, Xiaojia; Li, Wei; Xie, Weimin; Tong, Zhongsheng; Wang, Shusen; Xu, Faliang; Sun, Tao; Liu, Wei; Chen, Zhendong; Wu, Jinsheng; Wang, Ying; Wang, Haixia; Yan, Min; Wang, Xinshuai; Wang, Jingfen; Cao, Feilin; Du, Yingying; Zhang, Yongqiang; Chen, Lilin; Lu, Ping; Sun, Sanyuan; Zhang, Ruiwen; Zang, Aimin; Nie, Xiuqing; Lei, Yuan
HER2
肿瘤
肿瘤免疫
乳腺癌
发表日期：2025
文献求助 收藏

Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01

达托泊单抗德鲁替康对比化疗治疗既往接受过治疗的不可手术/转移性激素受体阳性、人表皮生长因子受体2阴性乳腺癌：TROPION-Breast01研究的主要结果

期刊:Journal of Clinical Oncology
影响因子:41.9
doi:10.1200/JCO.24.00920
Bardia, Aditya; Jhaveri, Komal; Im, Seock-Ah; Pernas, Sonia; De Laurentiis, Michelino; Wang, Shusen; Martínez Jañez, Noelia; Borges, Giuliano; Cescon, David W; Hattori, Masaya; Lu, Yen-Shen; Hamilton, Erika; Zhang, Qingyuan; Tsurutani, Junji; Kalinsky, Kevin; Rubini Liedke, Pedro Emanuel; Xu, Lu; Fairhurst, Rick M; Khan, Sabrina; Denduluri, Neelima; Rugo, Hope S; Xu, Binghe; Pistilli, Barbara
肿瘤
肿瘤免疫
信号转导
乳腺癌
Human
免疫/内分泌
发表日期：2025
文献求助 收藏

Utidelone Plus Bevacizumab for ERBB2-Negative Metastatic Breast Cancer and Active Brain Metastases: The U-BOMB Phase 2 Nonrandomized Clinical Trial

乌替隆联合贝伐单抗治疗ERBB2阴性转移性乳腺癌和活动性脑转移：U-BOMB II期非随机临床试验

期刊:Jama Oncology
影响因子:20.1
doi:10.1001/jamaoncol.2025.1694
Yan, Min; Lv, Huimin; Liu, Xinlan; Wang, Shusen; Geng, Cuizhi; Song, Yuhua; Liu, Zhenzhen; Niu, Limin; Zhang, Mengwei; Wang, Chengzheng; Feng, Yajing; Zeng, Huiai; Sun, Huihui; Wang, Jing; Xiang, Yufen; Tang, Li; Qiu, Rongguo
肿瘤
肿瘤免疫
ERBB2
神经科学
乳腺癌
发表日期：2025
文献求助 收藏